Gregory Daniel, PhD, MPH, serves as Vice President, Head of Policy Innovation, Evidence & Engagement at Eli Lilly and Company. In this role, Greg leads efforts in policy innovation and thought leadership, policy evidence development, and external engagement to promote innovation and improve access and affordability in healthcare. Additionally, Greg has led Eli Lilly’s Global Public Policy group, where he led coordination and management of public policy issues to the company and industry in critical areas such as prescription drug pricing, access, affordability, and global value-based healthcare.
Beyond his leadership at Eli Lilly, Greg contributes extensively to the scientific and policy fields. He is the Editor-in-Chief of Therapeutic Innovation and Regulatory Science (TIRS), the scientific, peer-reviewed journal of DIA. He also serves on the Board of Directors and is a Past Chair for the Center for Innovation & Value Research (CIVR). His academic contributions include roles as Adjunct Associate Professor at the Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, and Visiting Scholar at the Center of Innovation in Regulatory Science at the Duke-National University of Singapore.
Greg has 25 years of experience and expertise leading pharmaceutical and medical device evidence and public policy. Prior to joining Lilly, he held leadership and executive roles within the medical device industry, academia, policy think tanks, and the commercial payer industry. At Edwards Lifesciences, he was Head of US Healthcare Policy. He also held roles as Deputy Center Director and Clinical Professor at the Duke-Margolis Institute for Health Policy, and as Fellow and Managing Director at the Center for Health Policy at the Brookings Institution. Prior to that, Greg directed real-world evidence generation, health economics and outcomes research, and pharmacoepidemiology studies as Vice President, Government and Academic Research, at Carelon (formerly HealthCore and a subsidiary of Elevance).
Greg earned his PhD in pharmaceutical economics, policy, and outcomes from the University of Arizona. Additionally, he holds an MPH with a focus in biostatistics, along with an MS and BS in Pharmacy, all from The Ohio State University.
